Cite
HARVARD Citation
McInnes, I. et al. (n.d.). 263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period. Rheumatology. p. . [Online].